SRRK

49.0102.70%
VS

Vikas Sinha

CFO & Treasurer

Mr. Vikas Sinha, M.B.A., C.A., CPA, is Director of Ray Therapeutics, Inc. from May 2026. He has extensive of executive leadership experience in the life sciences industry, with a proven track record across finance, investor relations, business development, strategy, IT and human resources. He is Co-Founder and Director of ElevateBio, LLC and had been its Chief Financial Officer since December 2017 until April 2025. He is Chief Financial Officer of Scholar Rock Holding Corporation from April 27, 2025 and is also its Treasurer. He is Chief Financial Officer of Scholar Rock, Inc. from April 27, 2025. He is Director of Orna Therapeutics, Inc. from January 2025. Mr. Sinha was CEO of AlloVir, Inc. from December 19, 2024 and was its Director since January 2019 and served as its President and Chief Financial Officer since January 2019. He is a Director at BCLS Acquisition Corp. since October 2020. He served as Treasurer and Secretary of Vanqua Bio, Inc. He serves as the Director at LifeEDIT, LLC. He served as the Executive Partner at MPM Capital. He joined MPM in 2018 as a Managing Director. He served as the Chief Financial Officer of Alexion Pharmaceuticals, Inc. from September 2005 to December 12, 2016, where he was responsible for finance, business development, strategy, investor relations and IT and served as its Executive Vice President from October 2012 to December 12, 2016. Mr. Sinha is responsible for financial and business risk management, strategic planning, contracting, customer services, information systems, supply chain and site administration in North America. Mr. Sinha has experience working in senior finance roles in the life sciences industry. He served as Senior Vice President of Alexion Pharmaceuticals, Inc., from September 2, 2005 to October 2012. Mr. Sinha also served at Bayer AG since June, 1994 holding various positions within Alexion Pharmaceuticals, Inc. in the United States, Japan, Germany and Canada. He has been Vice President and Chief Financial Officer of Bayer Pharmaceuticals Corporation, USA since February, 2001. He also serves as a board member for ElevateBio LLC since December 2017. He served as Principal Accounting Officer of Alexion Pharmaceuticals, Inc. until August 1, 2007. He was also a member of the Pharmaceutical Management Committee for North America. Prior to his appointment in the United States, Mr. Sinha served as Vice President and Chief Financial Officer of Bayer Yakuhin Ltd., in Japan and Manager, Mergers and Acquisitions with Bayer AG in Germany. He began his career at Bayer in Toronto as part of an executive development program in the healthcare division. Prior to his time at Bayer AG, he worked at ANZ Bank as a Senior Manager in Corporate Banking and at Citibank as an analyst. He serves as an Independent Non-Executive Director of Verona Pharma plc since September 12, 2016. Mr. Sinha joined the Verona Pharma plc on September 12, 2016. He is a member of the board of directors of Bain Capital Life Sciences Acquisition Inc. He serves as a Director of Alexion Pharma HoldingStemcentrx Inc. He served as Director of Vanqua Bio, Inc. He is also a qualified Chartered Accountant from the Institute of Chartered Accountants of India and a Certified Public Accountant in the United States. Mr. Sinha holds a Masters of Business Administration from the Asian Institute of Management, which included an exchange program with the University of Western Ontario (Richard Ivey School of Business).

Positions